Modulation of Reoviral Cytolysis (I): Combination Therapeutics
Viruses · 2023
DOI: 10.3390/v15071472 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Yoshinori Mori und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada. Hauptthemen laut MEDLINE: Stomach Neoplasms, Oncolytic Virotherapy, Orthoreovirus, Reoviridae. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, the Canadian Breast Cancer Foundation, the Cancer Research Society.
Abstract (Originalsprache)
Patients with stage IV gastric cancer suffer from dismal outcomes, a challenge especially in many Asian populations and for which new therapeutic options are needed. To explore this issue, we used oncolytic reovirus in combination with currently used chemotherapeutic drugs (irinotecan, paclitaxel, and docetaxel) for the treatment of gastric and other gastrointestinal cancer cells in vitro and in a mouse model. Cell viability in vitro was quantified by WST-1 assays in human cancer cell lines treated with reovirus and/or chemotherapeutic agents. The expression of reovirus protein and caspase activity was determined by flow cytometry. For in vivo studies, athymic mice received intratumoral injections of reovirus in combination with irinotecan or paclitaxel, after which tumor size was monitored. In contrast to expectations, we found that reoviral oncolysis was only poorly correlated with Ras pathway activation. Even so, the combination of reovirus with chemotherapeutic agents showed synergistic cytopathic effects in vitro, plus enhanced reovirus replication and apoptosis. In vivo experiments showed that reovirus alone can reduce tumor size and that the combination of reovirus with chemotherapeutic agents enhances this effect. Thus, we find that oncolytic reovirus therapy is effective against gastric cancer. Moreover, the combination of reovirus and chemotherapeutic agents synergistically enhanced cytotoxicity in human gastric cancer cell lines in vitro and in vivo. Our data support the use of reovirus in combination with chemotherapy in further clinical trials, and highlight the need for better biomarkers for reoviral oncolytic responsiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
- Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan.
ORCID-Profile: Hiromi Kataoka, Randal N Johnston
Förderung
- CIHR
- the Canadian Breast Cancer Foundation
- the Cancer Research Society
- Canadian Institutes of Health Research (RNJ)
Zitieren
APA
Mori, Y., Nishikawa, S. G., Fratiloiu, A. R., Tsutsui, M., Kataoka, H., Joh, T., & Johnston, R. N. (2023). Modulation of Reoviral Cytolysis (I): Combination Therapeutics. Viruses. https://doi.org/10.3390/v15071472
Vancouver
Mori Y, Nishikawa SG, Fratiloiu AR, Tsutsui M, Kataoka H, Joh T, et al. Modulation of Reoviral Cytolysis (I): Combination Therapeutics. Viruses. 2023. doi:10.3390/v15071472
BibTeX
@article{Mori2023,
author = {Mori, Yoshinori and Nishikawa, Sandra G and Fratiloiu, Andreea R and Tsutsui, Mio and Kataoka, Hiromi and Joh, Takashi and Johnston, Randal N},
title = {Modulation of Reoviral Cytolysis (I): Combination Therapeutics},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15071472}
}
EUVIMED